Anlon Healthcare Q1 FY27 Investor Presentation

65 commercialized products, 28 in pilot stage, and 49 under lab testing.
Served 125 customers to date (directly & indirectly).
Installed production capacity of 1,400-1,600 MTPA with a utilization rate of 62.37%.
Key drivers include three strategic acquisitions (Bizotic, Apiqo, Remember India) for capacity expansion and backward integration, and 21 global DMF filings.

The company operates across APIs, Pharmaceutical Intermediates, and is expanding into Finished Dosage Formulations (FDFs).
Significant growth is driven by the acquisition of Remember India Health Links, which had an FY25 turnover of ₹83.08 Lakhs from tablets, capsules, and formulations.

Q1 FY27 Consolidated Revenue: ₹87.62 crore.
Q1 FY27 Consolidated PAT: ₹8.28 crore (PAT Margin: 9.45%).
Q1 FY27 Consolidated EBITDA: ₹15.65 crore (EBITDA Margin: 17.86%).
Q1 FY27 EPS: ₹0.16.
YoY Comparison: Q1 FY26 Revenue was ₹33.31 crore, PAT was ₹3.55 crore, and EBITDA was ₹6.26 crore.
Full Year FY26 Consolidated Revenue: ₹171.97 crore; PAT: ₹29.09 crore (PAT Margin: 16.89%); EBITDA: ₹47.77 crore (EBITDA Margin: 27.74%).
Drivers of financial performance: Revenue growth supported by acquisitions, improved product mix, and operational leverage.
Key Risks: Not explicitly disclosed in the presentation.

Net Worth: ₹254.79 crore.
Total Assets: ₹373.97 crore.
Non-Current Assets: ₹65.70 crore (including Fixed Assets: ₹57.76 crore).
Current Assets: ₹308.26 crore (including Inventories: ₹113.16 crore; Trade Receivables: ₹103.68 crore; Cash & Bank Balance: ₹4.37 crore).
Total Liabilities: ₹373.97 crore.
Non-Current Liabilities: ₹11.61 crore (including Long-Term Borrowings: ₹6.09 crore).
Current Liabilities: ₹107.57 crore (including Short-Term Borrowings: ₹37.56 crore; Trade Payables: ₹42.19 crore).
Financial Health Insights: Improved net worth and asset base post-acquisitions.

Capital Expenditure: Not specified for future periods. Acquisitions were made for capacity expansion (Bizotic: ₹3.79 crore; Apiqo: ₹5.40 crore).
Free Cash Flow: Not specified.
Operating Cash Flow: Not specified.
Net Debt Movement: Long-Term Borrowings reduced from ₹54.25 crore in FY24 to ₹6.09 crore in FY26.
Investment Rationale: Focus on capacity expansion via acquisitions (greenfield risk reduction) and backward integration.

Investments in Innovation: 4 in-house R&D centers; 11 fume cupboards; developing 3 molecules for 2 global innovator companies as CDMO projects.
Expected impact on growth: New product launches and DMF filings to support ~30% revenue CAGR.
Strategic Rationale: Transition from API-focused to integrated pharmaceutical company; diversification into Industrial & Fine Chemicals; expanding into high-growth regulated markets.

Macro/Industry Trends: Global pharma market to grow from USD 1.99 trillion in 2025 to USD 4.03 trillion by 2034 (8.19% CAGR); Global APIs market to reach USD 447.40 billion by 2035 (6.79% CAGR); India APIs market projected at USD 41.60 billion by 2034 (7.78% CAGR).
Impact on Company: China+1 strategy, government PLI schemes (USD 2.04 billion outlay), and rising generic drug demand present significant growth opportunities for compliant manufacturers like Anlon.

Strategic Outlook: Company is poised to deliver ~30% revenue CAGR over the next three years.
FY Guidance: Target sustainable EBITDA margin of 25-30%; launch of 7 new APIs in FY 2026-27; 3-5 DMF filings planned in FY 2026-27.
Market Share Targets: Not explicitly stated.
Risks and Opportunities: Focus on reducing pharma-cycle dependence through diversification into Industrial & Fine Chemicals and FDFs.